Minerva Neurosciences to Report Third Quarter 2022 Financial Results and Business Updates on November 9, 2022
November 02 2022 - 8:30AM
Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage
biopharmaceutical company focused on the development of therapies
to treat central nervous system (CNS) disorders, today announced
that it will release financial results and business updates for the
third quarter of 2022 on Wednesday, November 9, 2022. The
Company will host a webcast that day at 8:30 a.m. Eastern
Time to discuss the results and updates.
The live conference call may be
accessed here and the webcast is available on
the Company’s website under Events and Presentations.
The archived webcast will be available on the Company’s website
beginning approximately two hours after the event for 90 days.
About Minerva Neurosciences
Minerva Neurosciences, Inc. (Nasdaq: NERV) is a clinical-stage
biopharmaceutical company focused on developing product candidates
to treat central nervous system (CNS) diseases. Our goal is to
transform the lives of patients with improved therapeutic options.
Minerva’s portfolio of compounds includes roluperidone (MIN-101),
in clinical development for negative symptoms of schizophrenia, and
MIN-301, in pre-clinical development for Parkinson’s
disease. For more information, please visit our website.
For more information:
Investor inquiries:Fred AhlholmCFO, Minerva
Neurosciencesinfo@minervaneurosciences.com
Media Inquiries:Helen ShikPrincipal, Shik Communications LLC
helen@shikcommunications.com
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From Apr 2024 to May 2024
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From May 2023 to May 2024